Skip to main
CNMD
CNMD logo

CONMED (CNMD) Stock Forecast & Price Target

CONMED (CNMD) Analyst Ratings

Based on 5 analyst ratings
Hold
Strong Buy 0%
Buy 20%
Hold 80%
Sell 0%
Strong Sell 0%

Bulls say

Conmed Corp has demonstrated strong growth in its high-demand segments, highlighted by double-digit increases in Foot & Ankle and significant growth from its BioBrace product line, which is set for a full release in Q3'25 following its FDA approval. Despite facing supply constraints, the company has shown resilience and positive performance trends, indicating an easing of these challenges. Furthermore, management's conservative revenue guidance suggests a strategic focus on sustained gradual growth, reinforcing confidence in the firm's ongoing top-line turnaround efforts.

Bears say

Conmed Corp has experienced a significant decline in stock value, with shares down approximately 27% year-to-date, indicating ongoing challenges in the company's turnaround efforts. The recent shift in price target from $80 to $68 reflects a valuation based on around 15 times the fiscal year 2025 earnings per share estimate of $4.46, signifying a negative sentiment regarding future profitability. Additionally, capital weakness noted, particularly in international markets, appears to stem from challenging year-over-year comparisons rather than an overall reduction in hospital capital budgets, suggesting persistent competitive pressures and operational hurdles.

CONMED (CNMD) has been analyzed by 5 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 20% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CONMED and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CONMED (CNMD) Forecast

Analysts have given CONMED (CNMD) a Hold based on their latest research and market trends.

According to 5 analysts, CONMED (CNMD) has a Hold consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $54, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $54, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CONMED (CNMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.